Abstract: Methods, systems, and apparatus, including computer programs encoded on computer storage media, for source data review and document compliance. The computer obtains a plurality of source documents, each source document comprising clinical trial information of the one or more clinical studies. The computer identifies, for each source document and by a natural language processing (NLP) model, a plurality of entities of the one or more clinical studies from the information related to the participants of the one or more clinical studies in the source document. The computer generates an updated NLP models configured to detect one or more events likely to have occurred among the plurality of entities, each event being associated with at least one entity from the plurality of entities. The updated NLP model is configured to update parameters in response to receiving a user input representing feedback to a model output from the updated NLP model.

Abstract: Techniques for managing an application token may include providing, by a first service provider application on a communication device to a first service provider computer, a first request for a first application token, receiving, by an account management application on the communication device from a token service computer in communication with the first service provider computer, the first application token, and storing the first application token in a token container in the account management application.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present invention provides a stabilising composition, comprising: a) a first phenolic antioxidant comprising one or more phenolic compounds having the structure of formula (I): ?wherein R1 is a linear or branched alkyl group having from 12 to 20 carbon atoms; and b) one or more second phenolic antioxidants independently selected from: ?a mono-hydroxybenzene having lower steric hindrance than the first phenolic antioxidant; ?a di-hydroxybenzene; and/or ?a tri-hydroxybenzene.

Abstract: The present invention relates to stabilising compositions, particularly stabilising compositions which can be used to stabilise insulation or semi-conductive compositions, such as are used for electrically insulating wires and cables. The stabilising composition comprises: a first stabilising component comprising at least one fully hindered phenolic antioxidant; a second stabilising component comprising at least one partially hindered phenolic antioxidant; and a third stabilising component comprising at least one sulphur-containing antioxidant.

Abstract: Techniques for managing an application token may include providing, by a first service provider application on a communication device to a first service provider computer, a first request for a first application token, receiving, by an account management application on the communication device from a token service computer in communication with the first service provider computer, the first application token, and storing the first application token in a token container in the account management application.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody, atezolizumab, and bevacizumab.

Abstract: The present disclosure relates to methods of treating cancer comprising administering to a subject an anti-IL-27 antibody and pembrolizumab.

Abstract: The invention concerns an antidegradant blend for polymers, comprising: a. an antioxidant selected from one or more of: i. a phenolic antioxidant; ii. an organic phosphite antioxidant; and: b. an inorganic antioxidant or reducing agent; wherein the composition is absent any metal carboxylate or buffering agent having the capacity to buffer in aqueous solution at a pH range from 4 to 8.

Abstract: Techniques for managing an application token may include providing, by a first service provider application on a communication device to a first service provider computer, a first request for a first application token, receiving, by an account management application on the communication device from a token service computer in communication with the first service provider computer, the first application token, and storing the first application token in a token container in the account management application.

Abstract: The present invention relates to a precursor material for an insulation composition, comprising: a crosslinkable graft polymer comprising a polyolefin component and a polyene component; and an antioxidant. The present invention also relates to an insulation composition obtained from the precursor material.

Abstract: The present invention provides a stabilising composition, comprising: a) a first phenolic antioxidant comprising one or more phenolic compounds having the structure of formula (I): ?wherein R1 is a linear or branched alkyl group having from 12 to 20 carbon atoms; and b) one or more second phenolic antioxidants independently selected from: ?a mono-hydroxybenzene having lower steric hindrance than the first phenolic antioxidant; ?a di-hydroxybenzene; and/or ?a tri-hydroxybenzene.

Abstract: A load bearing flexible conduit system for use in a body of water and adapted for deployment from a reel located on a water going vessel into the body of water is disclosed. The system comprises a number of lengths of load bearing flexible conduit, each length of load bearing flexible conduit provided with an inner layer having a throughbore and a load bearing outer layer. A joint for connecting the lengths together has a body having a longitudinal axis and a throughbore and at least one flexible coupling to permit at least one of the ends of the respective first and second lengths of load bearing flexible conduit to move relative to the longitudinal axis of the joint.

Abstract: The invention provides a hydrolytically stabilised phosphite composition, comprising: a. a phosphite antioxidant which is a liquid at ambient conditions and comprises a blend of at least two different phosphites of Formula I: wherein R1, R2 and R3 are independently selected alkylated aryl groups of Formula II: wherein R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1 to C6 alkyl, provided that at least one of R4, R5 and R6 in each phosphite is selected from the group consisting of tert-butyl and/or tert-pentyl; and b. a nitrogen-containing compound comprising a nitrogen atom, wherein the nitrogen atom: i. has a pKaH value of from about 7 to about 11; and ii. is sp3 hybridised, and wherein the nitrogen-containing compound is absent any labile protons.

Abstract: Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.

Abstract: The present invention is directed to an antidegradant blend, comprising: at least one metal carboxylate; at least one inorganic phosphite; at least one phenolic antioxidant; and at least one organic phosphite antioxidant. As examples, the metal carboxylate may comprise a metal stearate, a metal lactate and/or a metal benzoate while the inorganic phosphite may comprise one or more metal hypophosphites.

Abstract: The invention concerns a stabilising composition, comprising: at least one antioxidant comprising one or more of: a phenolic antioxidant, a phosphite antioxidant, a sulphur-containing antioxidant, and an aminic antioxidant; and at least one buffering agent, wherein the buffering agent has the capacity to buffer in aqueous solution at a pH range from 4 to 8.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof at a dose of at least about 0.003 mg/kg to at least about 20 mg/kg.

Abstract: The present disclosure relates to anti-IL-27 antibodies, and antigen-binding portions thereof. The disclosure also relates to methods for treating or ameliorating one or more symptoms of a disease, such as cancer, by administering the antibodies or antigen-binding portion thereof. The disclosure also relates to methods for detecting IL-27 in, for example, a subject or a sample.